Pharmaceutical Preparations · NYSE
For the period ended December 31, 2025, ELI LILLY & Co reported $65.2 billion across 2 reportable segments: Net product revenue ($60.96B, 93.5%), Collaboration and Other Revenue ($4.22B, 6.5%). Net product revenue's share of the total is up from 89.2% for the period ended December 31, 2022.
For the period ended December 31, 2025, ELI LILLY & Co reported $65.2 billion across 5 geographies: U.S. ($43.48B, 66.7%), Europe ($11.56B, 17.7%), Rest of world ($6.06B, 9.3%), Japan ($2.13B, 3.3%), and 1 smaller geography. U.S.'s share of the total is up from 57.0% for the period ended December 31, 2019.
ELI LILLY & Co annual revenue by reportable segment, as disclosed in SEC filings.
| Segment | FY2022 | FY2023 | FY2024 | FY2025 | Share |
|---|---|---|---|---|---|
| Net product revenue | $25.46B | $28.81B | $40.75B | $60.96B | 93.5% |
| Collaboration and Other Revenue | $3.08B | $5.31B | $4.29B | $4.22B | 6.5% |
| Total | $28.54B | $34.12B | $45.04B | $65.18B |
ELI LILLY & Co annual revenue by geography, as disclosed in SEC filings.
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Share |
|---|---|---|---|---|---|---|
| U.S. | $16.81B | $18.19B | $21.79B | $30.38B | $43.48B | 66.7% |
| Europe | $4.78B | $4.30B | — | — | $11.56B | 17.7% |
| Rest of world | — | $2.85B | $12.33B | $14.67B | $6.06B | 9.3% |
| Other Foreign Countries | $2.70B | — | — | — | — | — |
| Japan | $2.37B | $1.75B | — | — | $2.13B | 3.3% |
| China | $1.66B | $1.45B | — | — | $1.95B | 3.0% |
| Total | $28.32B | $28.54B | $34.12B | $45.04B | $65.18B |
Extracted from the XBRL segment tags in the company’s SEC filings. Figures are as reported and are not restated or adjusted.
Data: SEC EDGAR (financials, KPIs, segments) · Yahoo Finance (price, splits, metrics, analyst estimates, news headlines). Not financial advice.